secwatch.observer — SEC 8-K summary
======================================

Issuer:     TuHURA Biosciences, Inc./NV (HURA)
CIK:        0001498382
Form:       8-K
Filed at:   2025-06-06T23:59:59+00:00
Accession:  0001193125-25-137135
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TuHURA raises $12.6M in private placement, $3M from warrants, tied to Phase 3 & merger milestones
--------------------------------------------------------------------------------

- Total offering $12.6M (4.76M shares + warrants at $2.65/unit). Initial closing $2.23M.
- $9M purchased in four tranches tied to milestones: FDA partial clinical hold lift, Phase 3 start, Kineta merger close.
- Remaining $3.7M due by Dec 31, 2025. Also received $3.0M from Feb 2025 warrant exercise.
- Proceeds to fund Kineta merger closing, Phase 3 trial of IFx-2.0, and advancement of KVA12123 to Phase 2.
- Warrants exercisable at $3.3125, 5-year term, subject to authorized share increase.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1498382/000119312525137135/0001193125-25-137135-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1498382/000119312525137135/d864561d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-137135

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer